Nivolumab,Relatlimab
bms
['sclc', 'nsclc', 'neopredict', 'lcsm,(-blcsm)', 'able,(-kable),(-eable)', 'nivo', ' 30p']
#esmo22 neopredict: randomised ph ii trial of nivo/rela v nivo in resectable early stage nsclc:
- 30pts in each arm - r0 resection rate 98%
- 12m os 96%; dfs 91% both arms - mpr/pcr 28% (nivo) 32% (nivo/rela) promising early results from neoadj pd-1/lag3 #lcsm 
Thoracic Oncologist focused on immunotherapy for lung cancer & immune toxicity at Beaumont RCSI Cancer Centre Dublin; Adjunct Professor Johns Hopkins University